GDTC offering history
Every offering-related filing in CytoMed Therapeutics Ltd’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 132 filings back to Sep 28, 2021.
| Date | Filing | What it means | |
|---|---|---|---|
| Aug 18, 2025 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Jun 23, 2025 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Jun 13, 2025 | F-3 → | REGISTERED | F-3 registration — capacity to sell shares, not a sale yet |
| Apr 17, 2023 | 424B4 → | EXECUTED | Final prospectus — offering priced (typical for IPOs and marketed share deals) |
| Mar 31, 2023 | FWP → | MARKETING | Free-writing prospectus — offering being marketed |
| Mar 31, 2023 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Mar 30, 2023 | F-1/A → | REGISTERED | F-1/A registration — capacity to sell shares, not a sale yet |
| Mar 28, 2023 | F-1/A → | REGISTERED | F-1/A registration — capacity to sell shares, not a sale yet |
| Mar 16, 2023 | F-1/A → | REGISTERED | F-1/A registration — capacity to sell shares, not a sale yet |
| Feb 27, 2023 | FWP → | MARKETING | Free-writing prospectus — offering being marketed |
| Feb 21, 2023 | F-1/A → | REGISTERED | F-1/A registration — capacity to sell shares, not a sale yet |
| Feb 1, 2023 | F-1/A → | REGISTERED | F-1/A registration — capacity to sell shares, not a sale yet |
| Nov 18, 2022 | F-1 → | REGISTERED | F-1 registration — capacity to sell shares, not a sale yet |
Two honest limits. (1) A 424B takedown can price shares or notes — EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
GDTC offering FAQ
When did GDTC last execute an offering?
Per SEC filings, CytoMed Therapeutics Ltd's most recent priced offering document is a 424B5 filed 2025-08-18. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did GDTC last announce or register an offering?
The most recent registration is a F-3 filed 2025-06-13. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.
Free to use. No account, no card.